What is Inhibrx Biosciences, Inc.'s clinical trials?

Inhibrx Biosciences, Inc. (INBX) reported clinical trials of $5.79M in Q1 2026.

How has Inhibrx Biosciences, Inc.'s clinical trials changed year-over-year?

Inhibrx Biosciences, Inc.'s clinical trials increased by 299.8% year-over-year, from $1.45M to $5.79M.

What is the long-term trend for Inhibrx Biosciences, Inc.'s clinical trials?

Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s clinical trials has grown at a -8.1% compound annual growth rate (CAGR), from $5.41M to $4.57M.

Inhibrx Biosciences, Inc. INBX Clinical trials

Other financials

Income statement

See full

Revenue--100%

Operating income-$30.9M+27.9%

Net income-$33.4M+22.8%

EPS (diluted)-$2.15+23.2%

Balance sheet

See full

Cash & equivalents$161.7M-25.3%

Total debt$180.9M+69.8%

Total equity-$21.0M-122%

Total assets$184.0M-24.2%

Cash flow

See full

Operating cash flow-$38.0M-5.9%

CapEx--100%

Free cash flow-$38.0M-5.9%

Valuation

See full

Market cap$1.4B+546%

Enterprise value$1.42B+1,233%

P/S1,073.7×-280×

Profitability

See full

Operating margin-10,386.5%-5,025pp

Net margin-10,773.5%-878,492pp

FCF margin-9,986.5%-4,727pp

Returns & leverage

See full

Return on equity-197.8%-2,158pp

Debt / equity13.4×+13.3×

Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept inhibrx:ClinicalTrailsPrepaidExpenseCurrent.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s clinical trials.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s clinical trials?: Inhibrx Biosciences, Inc. (INBX) reported clinical trials of $5.79M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s clinical trials changed year-over-year?: Inhibrx Biosciences, Inc.'s clinical trials increased by 299.8% year-over-year, from $1.45M to $5.79M.
What is the long-term trend for Inhibrx Biosciences, Inc.'s clinical trials?: Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s clinical trials has grown at a -8.1% compound annual growth rate (CAGR), from $5.41M to $4.57M.